Baxter International Inc vs Hut 8 Corp — how do they compare? Baxter International Inc trades at $26.98 (market cap $13.93B), while Hut 8 Corp trades at $91 (market cap $11.19B). The key difference: Baxter International Inc is the larger of the two by market cap, and Baxter International Inc pays a 0.15% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.
| BAX | HUT | |
|---|---|---|
Market Cap | $13.93B | $11.19B |
Sector | Health | Technology |
52-Week High | $28.35 | $133.02 |
52-Week Low | $15.80 | $21.37 |
Enterprise Value | $21.45B | $18.62B |
Dividend Yield | 0.15% | — |
Signals from Pluang's Aura AI — not financial advice
Baxter International (BAX) trades at $27.22, down 2.02% today, with a bullish technical signal and strong recent earnings beats. The company reported Q2 2026 EPS of $0.56, beating expectations of $0.3665, and raised full-year guidance. Despite negative net income margins and high P/E of 87.85, cash flow trends improved with 2026 net cash flow projected at $468 million. Recent news highlights a 7.4% surge on August 3, 2026, following positive quarterly results and a cash tender offer announcement.
The outlook is cautiously optimistic due to earnings momentum and raised guidance, but high valuation and persistent negative profitability pose risks. Analyst consensus is mixed with 41.67% buy ratings, a $25.43 price target, and institutional activity showing volatility. Key risks include margin pressures and debt levels, though operational improvements may support recovery.
HUT trades at $90.77, up 5.97% on the day, amid a broader neocloud stock rally. The technical picture is bearish with resistance at $92 and support at $87. Fundamentally, the company reported a net loss of $226.15 million in 2025 despite revenue growth, with a negative net income margin of -188.59%. Recent news highlights a significant $26.6 billion contracted backlog and $7.5 billion in project financing for AI data center development, driving investor optimism about its strategic pivot.
The outlook is mixed: strong analyst buy ratings (93.75%) and a $165.11 price target suggest upside, but persistent losses, high valuation ratios, and execution risks on new projects pose challenges. The stock's near-term direction will hinge on translating its AI infrastructure backlog into profitable growth and achieving positive cash flow.
Trailing returns across standard periods
Latest headlines on both assets
Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.
Read more on BAX →Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.
Read more on HUT →